PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Mukama, T.* ; Fortner, R.T.* ; Katzke, V.* ; Hynes, L.C.* ; Petrera, A. ; Hauck, S.M. ; Johnson, T.* ; Schulze, M.* ; Schiborn, C.* ; Rostgaard-Hansen, A.L.* ; Tjønneland, A.* ; Overvad, K.* ; Pérez, M.J.S.* ; Crous-Bou, M.* ; Chirlaque, M.D.* ; Amiano, P.* ; Ardanaz, E.* ; Watts, E.L.* ; Travis, R.C.* ; Sacerdote, C.* ; Grioni, S.* ; Masala, G.* ; Signoriello, S.* ; Tumino, R.* ; Gram, I.T.* ; Sandanger, T.M.* ; Sartor, H.* ; Lundin, E.* ; Idahl, A.* ; Heath, A.K.* ; Dossus, L.* ; Weiderpass, E.* ; Kaaks, R.*

Prospective evaluation of 92 serum protein biomarkers for early detection of ovarian cancer.

Br. J. Cancer (2022)
Publ. Version/Full Text Research data DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND: CA125 is the best available yet insufficiently sensitive biomarker for early detection of ovarian cancer. There is a need to identify novel biomarkers, which individually or in combination with CA125 can achieve adequate sensitivity and specificity for the detection of earlier-stage ovarian cancer. METHODS: In the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, we measured serum levels of 92 preselected proteins for 91 women who had blood sampled ≤18 months prior to ovarian cancer diagnosis, and 182 matched controls. We evaluated the discriminatory performance of the proteins as potential early diagnostic biomarkers of ovarian cancer. RESULTS: Nine of the 92 markers; CA125, HE4, FOLR1, KLK11, WISP1, MDK, CXCL13, MSLN and ADAM8 showed an area under the ROC curve (AUC) of ≥0.70 for discriminating between women diagnosed with ovarian cancer and women who remained cancer-free. All, except ADAM8, had shown at least equal discrimination in previous case-control comparisons. The discrimination of the biomarkers, however, was low for the lag-time of >9-18 months and paired combinations of CA125 with any of the 8 markers did not improve discrimination compared to CA125 alone. CONCLUSION: Using pre-diagnostic serum samples, this study identified markers with good discrimination for the lag-time of 0-9 months. However, the discrimination was low in blood samples collected more than 9 months prior to diagnosis, and none of the markers showed major improvement in discrimination when added to CA125.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
9.075
0.000
6
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Trial
Language english
Publication Year 2022
HGF-reported in Year 2022
ISSN (print) / ISBN 0007-0920
e-ISSN 1532-1827
Journal British Journal of Cancer BJC
Publisher Nature Publishing Group
Publishing Place Campus, 4 Crinan St, London, N1 9xw, England
Reviewing status Peer reviewed
Institute(s) CF Metabolomics & Proteomics (CF-MPC)
POF-Topic(s) 30203 - Molecular Targets and Therapies
PSP Element(s) A-630700-001
Grants RCUK | Medical Research Council (MRC)
Cancer Research UK (CRUK)
DOI 10.1038/s41416-021-01697-z
WOS ID WOS:000742583500001
Scopus ID 85122722777
PubMed ID 35031764
Erfassungsdatum 2022-05-31
[➜Report correction]